Field evaluation of a topical combination of ivermectin, imidacloprid, and praziquantel for flea control in cats under routine clinical.

Abstract

Introduction: Flea infestation remains a major clinical and public health concern in cats due to its negative impact on animal welfare and its role in the transmission of zoonotic pathogens. Effective flea control under routine field conditions is essential for integrated parasite management in companion animals. The aim of this study was to evaluate the clinical performance of a topical formulation combining ivermectin, imidacloprid, and praziquantel for flea control in domestic cats under field conditions.

Methods: A total of 142 naturally infested cats of varying ages, sexes, and body conditions were included in the study. All animals received a single topical application of the evaluated formulation. Clinical and parasitological assessments were performed on Days 0, 1, 7, 14, and 30 post-treatment using standardized flea counts, pruritus scores, and dermatological lesion scores. Treatment effectiveness was assessed using within-subject pre-post comparisons. Effective flea control was defined as a marked reduction in the proportion of flea-positive cats relative to baseline, accompanied by concurrent clinical improvement.

Results: The proportion of cats free of detectable fleas exceeded 91% by Day 7 and approached 95% by Day 30 post-treatment. Significant clinical improvement was observed during the first two weeks, including reductions in pruritus intensity and dermatological lesion scores. Treatment response did not differ according to sex or age, indicating consistent clinical performance across diverse feline subpopulations. No adverse effects were reported throughout the study period.

Discussion: The findings indicate that the evaluated topical combination provides consistent and clinically meaningful flea control in domestic cats under routine field conditions, supporting its use as part of integrated parasite management strategies in companion animals. However, the absence of a negative control or active comparator group represents a limitation of the study; therefore, treatment effectiveness was assessed using within-subject comparisons rather than established regulatory efficacy benchmarks.